ABSTRACT
OBJECTIVE:To evaluate the cost-effectiveness of 3 therapeutic schemes in the treatment of Parkinson's disease (PD). METHODS:A total of 94 PD cases were randomly assigned into 3 groups:Group A (Benserazide tablets +carbidopa and Levodopa controlled release tablets),Group B (Benserazide tablets+Carbidopa and Levodopa controlled release tablets+Selegiline tablets) and Group C (Benserazide tablets+Carbidopa and Levodopa controlled release tablets+Entacapone tablets). After treatment for 8 weeks,the cost-effectiveness analysis were conducted for all the 3 groups. RESULTS:For Group A,B and C,the costs were 448.78,803.89,1 559.89 yuan,respectively; the total effective rates were 56.67%,83.33% and 85.71%,respectively; the cost-effectiveness ratios were 791.92,964.71,1 819.96,respectively. The incremental cost-effectiveness ratios of Group B and C were 1 332.00 and 3 826.14,respectively as against Group A. CONCLUSION:Group B is preferable for PD among the 3 groups.
ABSTRACT
OBJECTIVE:To Study the cost-effectiveness among3therapeutical schemes in the treatment of Graves ophthalmopathy.METHODS:A total of94cases with Graves ophthalmopathy were randomized into3groups,Group A was assigned to receive medrat,Group B to receive dexamethasone and Group C to receive prednisone,the outcomes were evaluated in terms of the cost-effectiveness analysis.RESULTS:The costs for Group A,B and C were2956.76yuan,2059.42yuan and31.09yuan,respectively.The total effective rates were93.94%,93.75%and51.72%,respectively.The cost-effec-tiveness ratios were31.47yuan,21.97yuan and0.60yuan,respectively.The incremental cost-effectiveness ratios of Group A and B were69.30yuan and48.26yuan,respectively as against Group C.CONCLUSION:In terms of pharmacoeconomics,Group B is comparatively the best option in treating Graves ophthalmopathy.